Evoke Pharma to Participate in Global Investment Conference
Evoke Pharma, Inc. (NASDAQ: EVOK), a company focused on developing innovative treatments for gastrointestinal disorders, is gearing up for a major investment event. This year, they will take part in the 26th Annual Global Investment Conference hosted by H.C. Wainwright, which will be held in New York City.
Conference Details and Key Highlights
The management team at Evoke Pharma will be actively involved in this important conference from September 9 to September 11. They will highlight recent developments related to their leading product, GIMOTI, a nasal spray designed to alleviate symptoms associated with diabetic gastroparesis.
Access to On-Demand Presentation
Registered attendees will have the chance to view Evoke's presentation on-demand, starting on September 9 at 7:00 a.m. ET, via the conference platform. This is a great opportunity for investors to gain valuable insights into Evoke’s advancements and trajectory in the pharmaceutical industry.
One-on-One Meetings with Investors
Throughout the conference, Evoke’s management will also be available for one-on-one meetings with prospective investors. These sessions aim to facilitate meaningful discussions about future opportunities and growth strategies for Evoke Pharma.
About Evoke Pharma, Inc.
Evoke Pharma is dedicated to creating pharmaceutical solutions that address gastrointestinal disorders. The company has successfully launched GIMOTI, a groundbreaking nasal spray formulation of metoclopramide, which offers relief to patients suffering from diabetic gastroparesis, a condition that disrupts normal stomach function.
Insights into Diabetic Gastroparesis
This disorder poses a significant health challenge for many, as it causes delayed gastric emptying and leads to various gastrointestinal symptoms. Previously, treatment options were limited to oral and injectable medications, but GIMOTI provides a more user-friendly alternative.
Ongoing Commitment to Patients
Evoke Pharma is dedicated to improving patient outcomes and is focused on expanding its product line and market presence. The challenges faced by individuals with diabetic gastroparesis drive Evoke to continue innovating treatment approaches. GIMOTI is notable as the only FDA-approved treatment specifically for this condition, representing a major milestone for the company.
Contact Information
If you have any questions or wish to learn more about Evoke Pharma, please reach out to Daniel Kontoh-Boateng at DKB Partners. He can be reached at 862-213-1398 or via email at dboateng@dkbpartners.net.
Frequently Asked Questions
What is GIMOTI?
GIMOTI is a nasal spray formulation of metoclopramide aimed at treating symptoms of diabetic gastroparesis, a condition that leads to delayed gastric emptying.
When will Evoke present at the conference?
Evoke's presentation will be available on-demand starting on September 9, 2024, at 7:00 a.m. ET.
What is diabetic gastroparesis?
Diabetic gastroparesis is a condition that impairs the stomach's ability to empty properly, resulting in various digestive complications.
How can investors connect with Evoke Pharma?
Investors can meet with Evoke's management during one-on-one meetings scheduled throughout the conference.
Who can I contact for more information about Evoke?
For additional inquiries about Evoke Pharma, you can contact Daniel Kontoh-Boateng at DKB Partners at 862-213-1398 or email him at dboateng@dkbpartners.net.
